title: [Effect of matrine on NO and ADMA metabolism pathways in serum and tissues of mice with lipopolysaccharide-induced intestine tissue inflammation].
abstract: OBJECTIVE
  To discuss the effect of matrine on nitric oxide (NO) and asymmetric methylarginine (ADMA) metabolism pathways in serum and tissues of mice with lipopolysaccharide (LPS) -induced intestine tissue inflammation.
  
  
  METHODS
  Kunming mice were randomly divided into five groups: the normal control group, the LPS group and matrine (80, 40, 20 mg x kg(-1) x d(-1)) groups. The mice were intragastrically administered with drugs for 3 d (distilled water of the same volume for the normal control group and the LPS group). One hour after the last intragastrical administration, normal saline or LPS (1 mg x kg(-1)) were intraperitoneally injected. Twelve hours later, serum and tissues were collected to determine NO and ADMA levels and observe the pathological changes of intestinal tissues. The Western blot method was adopted to detect the protein expressions of arginine methyltransferases 1 (PRMT1) and dimethylarginine dimethylaminohydrolase 2 (DDAH2) in intestinal tissues.
  
  
  RESULTS
  Compared with the model group, matrine (80, 40, 20 mg x kg(-1) x d(-1)) groups showed lower NO content in serum and tissues, higher ADMA level in serum and increased PRMT1 expression in intestinal tissues, but without effect on DDAH2 expression.
  
  
  CONCLUSIONS
  Matrine could inhibit LPS-induced intestine tissue inflammation in mice. Its action mechanism is related to the decreased NO content in serum and tissues and increased ADMA level in serum and PRMT1 expression in intestinal tissues.
authors.forename: Yang
authors.initials: Y
authors.lastname: Wu
authors.forename: Yang
authors.initials: Y
authors.lastname: Wang
authors.forename: Yao
authors.initials: Y
authors.lastname: Zhang
authors.forename: Li-Ping
authors.initials: LP
authors.lastname: Chen
authors.forename: Ji-Yong
authors.initials: JY
authors.lastname: Wang
mesh_terms: D000470:Alkaloids / Q000008:administration & dosage*; D000818:Animals; D001120:Arginine / Q000031:analogs & derivatives* / Q000097:blood / Q000378:metabolism; D006801:Humans; D007249:Inflammation; D007410:Intestinal Diseases / Q000188:drug therapy* / Q000201:enzymology / Q000276:immunology / Q000378:metabolism; D007413:Intestinal Mucosa / Q000378:metabolism; D007422:Intestines / Q000187:drug effects / Q000201:enzymology / Q000276:immunology*; D008070:Lipopolysaccharides / Q000009:adverse effects*; D008297:Male; D051379:Mice; D009569:Nitric Oxide / Q000097:blood / Q000378:metabolism*; D011484:Protein-Arginine N-Methyltransferases / Q000235:genetics / Q000378:metabolism; D011807:Quinolizines / Q000008:administration & dosage*; D000093842:Matrines
chemical_list: D000470:Alkaloids; D008070:Lipopolysaccharides; D011807:Quinolizines; D009569:Nitric Oxide; C018524:N,N-dimethylarginine; D001120:Arginine; C546338:Prmt1 protein, mouse; D011484:Protein-Arginine N-Methyltransferases; D000093842:Matrines